February 10, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.




How Supplied


RIXUBIS (Coagulation Factor IX [Recombinant]) is an antihemophilic factor indicated for:

  • Control and prevention of bleeding episodes in adults with hemophilia B.
  • Perioperative management in adults with hemophilia B.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia B.

RIXUBIS is not indicated for induction of immune tolerance in patients with hemophilia B [see WARNINGS AND PRECAUTIONS].


For intravenous use after reconstitution only.

  • Each vial of RIXUBIS has the recombinant Factor IX (rFIX) potency in international units stated on the vial.
  • Initiate treatment under the supervision of a physician experienced in the treatment of hemophilia.
  • Dosage and duration of treatment with RIXUBIS depend on the severity of factor IX deficiency, the location and extent of bleeding, the patient's clinical condition, age, and pharmacokinetic parameters of factor IX, such as incremental recovery and half-life.
  • Dosing of RIXUBIS may differ from that of plasma-derived factor IX products [see CLINICAL PHARMACOLOGY]. Subjects at the low end of the observed factor IX recovery range may require dose adjustment of RIXUBIS.
  • Monitor patients using a factor IX activity assay to ensure that the desired factor IX activity plasma level has been attained. If necessary, adjust the dose and the frequency of repeated infusions as appropriate.
  • Evaluate the patient for the development of factor IX inhibitors if the expected factor IX activity plasma levels are not attained or if bleeding is not controlled with an appropriate dose [see WARNINGS AND PRECAUTIONS].

Dosing Guidelines

Calculating Initial Dose

The initial dose of RIXUBIS is calculated based on the empirical finding that one international unit of RIXUBIS per kg body weight is expected to increase the circulating level of factor IX by 0.9 international units/dL of plasma (0.9% of normal) in adult patients.

A guide for calculating the initial dose of RIXUBIS for treatment of bleeding episodes is as follows:

Initial Dose = body weight (kg) x desired factor IX increase (% of normal or IU/dL) x reciprocal of observed recovery (IU/kg per IU/dL)

Incremental Recovery in Previously Treated Patients (PTPs)

Base the calculation of the dose on the patient's individual incremental recovery using serial factor IX activity assays, due to the wide range of inter-individual differences in incremental recovery. Titrate the dose based on the patient's clinical response and individual pharmacokinetics, in particular incremental recovery and half-life.

For an incremental recovery of 0.9 international units/dL of plasma (0.9% of normal), the dose is calculated as follows:

Dose (international units) = body weight (kg) x desired factor IX increase (% of normal or IU/dL) x 1.1 dL/kg

Examples (assuming patient's baseline factor IX level is < 1% of normal):
  1. A dose of 4550 international units of RIXUBIS, administered to a 70 kg patient, should be expected to result in a peak post-infusion factor IX increase of 4550 international units x {[0.9 IU/dL]/[IU/kg]}/[70 kg] = 58.5 international units/dL (58.5 % of normal).
  2. A peak level of 70% is required in a 60 kg patient. The appropriate dose would be 60 kg x 70 international units/dL/{[0.9 IU/dL]/[IU/kg]} = 4667 international units.

Control And Prevention Of Bleeding Episodes And Perioperative Management

A guide for dosing RIXUBIS in the control and prevention of bleeding episodes and perioperative management is provided in Table 1 and Table 2, respectively. Ensure the factor IX activity level is achieved and maintained in the corresponding period.

Table 1 : Dosing for Control and Prevention of Bleeding Episodes

Type of Bleeding Episodes Circulating Factor IX Level Required (% or IU/dL) Dosing Interval (hours) Duration of Therapy (days)
Minor Uncomplicated hemarthrosis, superficial muscular or soft tissue 20-30 12-24 At least 1 day, until healing is achieved
Moderate Intramuscular or soft tissue with dissection, mucous membranes, hematuria 25-50 12-24 2-7 days, until bleeding stops and healing is achieved
Major Pharyngeal, retropharyngeal, retroperitoneal, CNS 50-100 12-24 7-10 days, until bleeding stops and healing is achieved
Adapted from Roberts and Eberst1

Table 2 : Dosing for Perioperative Management

Type of Surgery Circulating Factor IX Level Required (% or IU/dL) Dosing Interval (hours) Duration of Therapy (days)
e.q., tooth extraction
30-60 24 At least 1 day, until healing is achieved
e.g., intracranial, intraabdominal, intrathoracic, joint replacement
80-100 8-24 7-10 days, until bleeding stops and healing is achieved

Routine Prophylaxis

The dose for previously treated patients (PTPs) is 40 to 60 international units per kg twice weekly. Titration of dose may be necessary depending upon the individual patient's age, bleeding pattern, and physical activity.

Preparation And Reconstitution

The procedures below are provided as general guidelines for the preparation and reconstitution of RIXUBIS. Always work on a clean surface and wash hands before performing the following procedures:

  1. Use aseptic technique during reconstitution procedure.
  2. Allow the RIXUBIS vial (dry factor concentrate) and Sterile Water for Injection, USP vial (diluent) to reach room temperature.
  3. Remove caps from the factor concentrate and diluent vials.
  4. Cleanse stoppers with germicidal solution and allow to dry prior to use. Place the vials on a flat surface.
  5. Open the BAXJECT II device package by peeling away the lid, without touching the inside (Figure A). Do not remove the device from the package. Note that the BAXJECT II device is intended for use with a single vial of RIXUBIS and Sterile Water for Injection, USP only; therefore, reconstituting and withdrawing a second vial into the syringe requires a second BAXJECT II device.
  6. Turn the package over. Press straight down to fully insert the clear plastic spike through the diluent vial stopper (Figure B).
  7. Grip the BAXJECT II package at its edge and pull the package off the device (Figure C). Do not remove the blue cap from the BAXJECT II device. Do not touch the exposed white plastic spike.
  8. Turn the system over so that the diluent vial is on top. Quickly insert the white plastic spike fully into the RIXUBIS vial stopper by pushing straight down (Figure D). The vacuum will draw the diluent into the RIXUBIS vial.
  9. Swirl gently until the powder is completely dissolved. Do not refrigerate after reconstitution. Use within 3 hours of reconstitution.

Preparation And Reconstitution - Illustration


For intravenous bolus infusion only.

  • The safety and efficacy of RIXUBIS administration by continuous infusion has not been established.
  • Inspect parenteral drug products for particulate matter and discoloration prior to administration. The solution should be clear and colorless in appearance. Do not use RIXUBIS if you notice any particulates or turbidity in the solution and notify Baxter.
  • Perform product administration and handling of the administration set and needles with caution. Percutaneous puncture with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate medical attention if injury occurs. Place needles in a sharps container after single-use.
  • Administer RIXUBIS at room temperature and within 3 hours of reconstitution. Discard any unused product.
  1. Use a plastic syringe with this product.
  2. Remove the blue cap from the BAXJECT II device. Connect the syringe to the BAXJECT II device (Figure E). Do not inject air.
  3. Turn the system upside down (factor concentrate vial now on top). Draw the factor concentrate into the syringe by pulling the plunger back slowly (Figure F).
  4. Disconnect the syringe; attach a suitable needle and inject intravenously by bolus infusion. If a patient is to receive more than one vial of RIXUBIS, the contents of multiple vials may be drawn into the same syringe.
  5. Maximum infusion rate of 10 mL/min.

Administration - Illustration


Dosage Forms And Strengths

RIXUBIS is a white or almost white lyophilized powder in single-use vials containing nominally 250, 500, 1000, 2000 or 3000 international units.

RIXUBIS is available as single-use vials containing the following product strengths:

Color Code Nominal Strength (international units) Kit NDC
Light Blue 250 0944-3026-02
Pink 500 0944-3028-02
Green 1000 0944-3030-02
Orange 2000 0944-3032-02
Silver 3000 0944-3034-02

Actual factor IX activity in international units is stated on the unit carton and vial label.

Each kit also contains 5 mL of Sterile Water for Injection and a BAXJECT II transfer device.

Storage And Handling

  • Store at refrigerated temperature; 2° to 8°C (36° to 46°F) for up to 24 months. Do not freeze.
  • May store at room temperature not to exceed 30°C (86°F) for up to 12 months within the 24 month time period. Write on the carton the date RIXUBIS was removed from refrigeration.
  • After storage at room temperature, do not return the product to the refrigerator.
  • Do not use beyond the expiration date printed on the carton or vial.

Baxter Healthcare Corporation, Westlake Village, CA 91362 USA. Revised: Jan 2014

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 3/25/2014

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.